PJP Prophylaxis in Steroid Users

Indications for PJP Prophylaxis

The European League Against Rheumatism recommends PJP prophylaxis for patients receiving high-dose glucocorticoids (≥20 mg prednisone daily or equivalent) for ≥4 weeks, particularly when combined with other immunosuppressive agents 2, 3
The American College of Rheumatology suggests patients with autoimmune inflammatory rheumatic diseases on high-dose steroids (>15-30 mg prednisolone or equivalent for >2-4 weeks) should receive prophylaxis, especially when combined with other immunosuppressants 4
The National Comprehensive Cancer Network recommends considering PJP prophylaxis for patients with brain tumors requiring anti-edema treatment with dexamethasone, particularly during prolonged courses 1
The European Association for the Study of the Liver recommends liver transplant recipients receive PJP prophylaxis for 6-12 months post-transplantation 5

Persistent lymphopenia (<1000/ml) increases PJP risk and may necessitate longer prophylaxis, according to the American College of Rheumatology 1, 2, 4
Older age and pre-existing lung disease are additional risk factors that may warrant extended prophylaxis, as suggested by the European League Against Rheumatism 4
Concurrent use of other immunosuppressants with glucocorticoids significantly increases PJP risk, according to the National Comprehensive Cancer Network 2, 4
Patients with a history of previous PJP infection should receive lifelong prophylaxis to prevent recurrence, as recommended by the Centers for Disease Control and Prevention 6

The National Comprehensive Cancer Network recommends first-line prophylaxis with Trimethoprim-sulfamethoxazole (TMP-SMX), with standard dosing of one double-strength tablet (800mg SMX/160mg TMP) daily or three times weekly (Monday-Wednesday-Friday) 2, 3, 4
For TMP-SMX intolerance, the European League Against Rheumatism suggests alternative options such as Atovaquone 1500mg daily, Dapsone 100mg daily, or Aerosolized pentamidine 300mg monthly 2, 3

The American College of Rheumatology recommends discontinuing prophylaxis when steroid dose is tapered below 20mg prednisone daily or equivalent 2, 3
For patients with multiple risk factors (lymphopenia, concurrent immunosuppressants), the National Comprehensive Cancer Network suggests considering continuing prophylaxis until immunosuppression is adequately reduced 4
In patients with a history of PJP, the Centers for Disease Control and Prevention recommends continuing prophylaxis indefinitely 6

The National Comprehensive Cancer Network recommends complete blood count with differential and platelet count at initiation of TMP-SMX and monthly thereafter to assess for hematologic toxicity 4, 6
The European League Against Rheumatism suggests monitoring for adverse effects of prophylactic medications, particularly with TMP-SMX (rash, nausea, headache, cytopenia) 4
The American College of Rheumatology recommends being aware of potential drug interactions, particularly between TMP-SMX and methotrexate (increased risk of cytopenia) 4